dermavant®

Issued 9/2023

CORPORATE FACT SHEET

Dermavant Is Committed to Fostering Unprecedented Change and Unparalleled Impact in Immuno-Dermatology

We're doing this by thinking differently, pushing the boundaries of science and partnering with providers in new ways — all with one goal: transforming the lives of millions of patients with skin diseases.

At a Glance:

- A biopharmaceutical company
- Founded September 2015
- A subsidiary of Roivant Sciences
- U.S. operations in Long Beach, CA; Raleigh-Durham, NC; & Dallas, TX

About Dermavant

A Passion for Science and a Commitment to Dermatology

Dermavant Sciences, a subsidiary of Roivant Sciences, is a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology. Dermavant's focus is to develop therapies that have the potential to address unmet medical needs while driving greater efficiency in research and clinical development.

The company's medical dermatology pipeline includes commercialized, late-stage and early-development product candidates that target specific unmet needs in two of the largest growing immuno-dermatology markets — plaque psoriasis and atopic dermatitis — as well as other immunological and inflammatory diseases.

Dermavant launched its first product, VTAMA® (tapinarof) cream, 1%, for the topical treatment of plaque psoriasis in adults in 2022. Dermavant is also developing VTAMA cream for the treatment of atopic dermatitis in adults and children as young as 2 years old. Atopic dermatitis, the most common type of eczema, affects more than 9.6 million children and 16.5 million adults in the United States.

IMPORTANT SAFETY INFORMATION

Indication: VTAMA® (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque psoriasis in adults.
Adverse Events: The most common adverse reactions (incidence ≥ 1%) in subjects treated with VTAMA cream were folliculitis (red raised bumps around the hair pores), nasopharyngitis (pain or swelling in the nose and throat), contact dermatitis (skin rash or irritation, including itching and redness, peeling, burning, or stinging), headache, pruritus (itching), and influenza (flu).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For Medical Information, Adverse Event Reporting or Product Quality Complaints, call:
1-8-DERMAVANT (1-833-762-8268) Monday - Friday | 8 a.m.-8 p.m. ET

dermavant.com
medinfo@dermavant.com
@dermavant
@dermavant-sciences

dermavant®

Executive Leadership Team

Todd Zavodnick
Chief Executive Officer

Chris Chapman
Chief Commercial Officer

Chris Van Tuyl
Chief Legal Officer

Michael Swartzburg
Chief Financial Officer

David Rubenstein
Chief Scientific Officer

Philip Brown
Chief Medical Officer

Paul Seaback
Chief Technical Officer

Dermavant Has VTAMA Cream and Other Candidates in Development Addressing:

Plaque Psoriasis in Adults, Atopic Dermatitis and Immunological and Inflammatory Diseases

PRODUCT CANDIDATE	POTENTIAL INDICATION	STAGE OF DEVELOPMENT
		Preclinical · Phase 1 · Phase 2 · Phase 3 · FDA Review · Commercial
VTAMA® cream (DMVT-505) A topical aryl hydrocarbon receptor (AhR) agonist	Plaque Psoriasis in Adults	Phase 3 → Commercial
Tapinarof (DMVT-505) A topical aryl hydrocarbon receptor (AhR) agonist	Atopic Dermatitis	Phase 3
DMVT-506 Next-generation aryl hydrocarbon receptor (AhR) agonist under development for multiple routes of administration	Immunological and Inflammatory Diseases	Preclinical

Long Beach, CA
3780 Kilroy Airport Way
Suite 250
Long Beach, CA 90806
United States

Dallas, TX
2102 E State Hwy 114
Suite 217
Southlake, TX 76092
United States

Raleigh/Durham, NC
3300 Paramount Pkwy
Suite 150
Morrisville, NC 27560
United States

Basel, Switzerland
Viaduktstrasse 8
4051 Basel
Switzerland

US-CORP-2300054